Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy.

Joseph Tkacz¹, Alejandro Cajigal², Matthew Sidovar², Kathleen Wilson¹, Emma Pennington¹, Ilya Okunev¹, Kristin Gillard³

¹Inovalon, Bowie, MD, USA.

²Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ, 08540, USA.

³Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ, 08540, USA. kristin.gillard@bms.com.

PubMed PMC DOI PDF

Abstract

BACKGROUND/OBJECTIVE: Metabolic disorders are prevalent among the schizophrenia population due to relatively poor access to healthcare, lifestyle factors, genetics, and metabolic side effects associated with antipsychotic treatment. This study evaluated the rate, timing, and costs associated with the onset of metabolic disorders among individuals with schizophrenia newly initiating oral antipsycho…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.